Literature DB >> 2254131

The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART).

S Dische1, M I Saunders.   

Abstract

Continuous, hyperfractionated, accelerated radiotherapy (CHART) was devised to give the maximum chance of improving clinical radiotherapy and was based upon available radiobiological evidence. A pilot study, begun in 1985, has now included 210 patients. When comparison is made with previously treated cases, improved results have been seen in the two main groups included, that is, advanced head and neck and bronchial carcinomas. Multi-center randomized controlled clinical trials are planned.

Entities:  

Mesh：

Year:  1990        PMID： 2254131     DOI： 10.1016/0360-3016(90)90251-e

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


  5 in total

1.  Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.

Authors:  F Arias; G Asín; M I Uzcanga; E Maraví; I Quílez; V Chicata; C Eito; A Viudez; I Hernández; F Mañeru; M A Domínguez
Journal:  Clin Transl Oncol       Date:  2013-11-08       Impact factor: 3.405

2.  A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.

Authors:  Weisan Zhang; Qian Liu; Xifeng Dong; Ping Lei
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

3.  Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial.

Authors:  Fernando Arias de la Vega; Miguel Angel Domínguez Domínguez; Ana Manterola Burgaleta; Ruth Vera García; Maria Eugenia Echeverría Zabalza; Eugenio Oria Mundin; Enrique Martínez López; Pilar Romero Rojano; Elena Villafranca Iture
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

4.  Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck.

Authors:  M H Bennett; G D Wilson; S Dische; M I Saunders; C A Martindale; B M Robinson; A E O'Halloran; M D Leslie; J H Laing
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

Review 5.  Non-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand?

Authors:  R L Eakin; M I Saunders
Journal:  Ulster Med J       Date:  2000-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.